Page 84 - HIV/AIDS Guidelines

38. LathouwersE,DeMeyerS,DierynckI,etal.Virologicalcharacterizationofpatientsfailingdarunavir/ritonaviror
lopinavir/ritonavirtreatmentintheARTEMISstudy:96-weekanalysis.Antivir Ther.2011;16(1):99-108.
39. PanelonTreatmentofHIV-InfectedPregnantWomenandPreventionofPerinatalTransmission.Recommendationsfor
UseofAntiretroviralDrugsinPregnantHIV-1-InfectedWomenforMaternalHealthandInterventionstoReduce
PerinatalHIVTransmissionintheUnitedStates,Sep.14,2011;pp1-207.Availableat
http://aidsinfo.nih.gov/contentfiles/PerinatalGL.pdf.2011.
40. WormSW,SabinC,WeberR,etal.RiskofmyocardialinfarctioninpatientswithHIVinfectionexposedtospecific
individualantiretroviraldrugsfromthe3majordrugclasses:thedatacollectiononadverseeventsofanti-HIVdrugs
(D:A:D)study.J Infect Dis.Feb12010;201(3):318-330.

41. LangS,Mary-KrauseM,CotteL,etal.Impactofindividualantiretroviraldrugsontheriskofmyocardialinfarctionin
humanimmunodeficiencyvirus-infectedpatients:acase-controlstudynestedwithintheFrenchHospitalDatabaseon
HIVANRScohortCO4.Arch Intern Med.Jul262010;170(14):1228-1238.
42. FoodandDrugAdministration(FDA).Invirase(packageinsert).October2010.
http://www.accessdata.fda.gov/drugsatfda_docs/label/2010/020628s033,021785s010lbl.pdf.
43. ShulmanN,ZolopaA,HavlirD,etal.Virtualinhibitoryquotientpredictsresponsetoritonavirboostingofindinavir-
basedtherapyinhumanimmunodeficiencyvirus-infectedpatientswithongoingviremia.Antimicrob Agents Chemother.
Dec2002;46(12):3907-3916.
44. DragstedUB,GerstoftJ,PedersenC,etal.Randomizedtrialtoevaluateindinavir/ritonavirversussaquinavir/ritonavirin
humanimmunodeficiencyvirustype1-infectedpatients:theMaxCmin1Trial.J Infect Dis.Sep12003;188(5):635-642.
45. DragstedUB,GerstoftJ,YouleM,etal.Arandomizedtrialtoevaluatelopinavir/ritonavirversussaquinavir/ritonavirin
HIV-1-infectedpatients:theMaxCmin2trial.Antivir Ther.2005;10(6):735-743.
46. MalanDR,KrantzE,DavidN,WirtzV,HammondJ,McGrathD.Efficacyandsafetyofatazanavir,withorwithout
ritonavir,aspartofonce-dailyhighlyactiveantiretroviraltherapyregimensinantiretroviral-naivepatients.J Acquir
Immune Defic Syndr.Feb12008;47(2):161-167.
47. MolinaJM,Andrade-VillanuevaJ,EchevarriaJ,etal.Once-dailyatazanavir/ritonavirversustwice-daily
lopinavir/ritonavir,eachincombinationwithtenofovirandemtricitabine,formanagementofantiretroviral-naiveHIV-1-
infectedpatients:48weekefficacyandsafetyresultsoftheCASTLEstudy.Lancet.Aug232008;372(9639):646-655.
48. MolinaJM,Andrade-VillanuevaJ,EchevarriaJ,etal.Once-dailyatazanavir/ritonavircomparedwithtwice-daily
lopinavir/ritonavir,eachincombinationwithtenofovirandemtricitabine,formanagementofantiretroviral-naiveHIV-1-
infectedpatients:96-weekefficacyandsafetyresultsoftheCASTLEstudy.J Acquir Immune Defic Syndr. Mar1
2010;53(3):323-332.
49. Chan-TackKM,TruffaMM,StrubleKA,BirnkrantDB.Atazanavir-associatednephrolithiasis:casesfromtheUSFood
andDrugAdministration'sAdverseEventReportingSystem.AIDS.May312007;21(9):1215-1218.
50. OrtizR,DejesusE,KhanlouH,etal.Efficacyandsafetyofonce-dailydarunavir/ritonavirversuslopinavir/ritonavirin
treatment-naiveHIV-1-infectedpatientsatweek48.AIDS.Jul312008;22(12):1389-1397.

51. MillsAM,NelsonM,JayaweeraD,etal.Once-dailydarunavir/ritonavirvs.lopinavir/ritonavirintreatment-naive,HIV-
1-infectedpatients:96-weekanalysis.AIDS.Aug242009;23(13):1679-1688.

52. TrottierB,MachoufN,ThomasR,etal.Effectiveandsafeuseofabacavir/lamivudinefixed-dosecombinationwith
ritonavir-boostedDarunavir,anovelregimenforHIVtherapy.Paperpresentedat:6thInternationalAIDSSociety
ConferenceonHIVPathogenesis,Treatment,andPrevention;July17-20,2011;Rome,Italy.AbstractCDB333.
53. EronJ,Jr.,YeniP,GatheJ,Jr.,etal.TheKLEANstudyoffosamprenavir-ritonavirversuslopinavir-ritonavir,eachin
combinationwithabacavir-lamivudine,forinitialtreatmentofHIVinfectionover48weeks:arandomisednon-
inferioritytrial.Lancet.Aug52006;368(9534):476-482.
54. PulidoF,EstradaV,BarilJG,etal.Long-termefficacyandsafetyoffosamprenavirplusritonavirversuslopinavir/ritonavir
incombinationwithabacavir/lamivudineover144weeks.HIV Clin Trials.Mar-Apr2009;10(2):76-87.
Guidelines for the Use of Antiretroviral Agents in HIV-1-Infected Adults and Adolescents F-23

Downloaded from http://aidsinfo.nih.gov/guidelines on 12/8/2012 EST.